Cyclerion Therapeutics Inc CYCN shares are trading higher Friday morning after the company announced it will present a trial design for its CY6463 Phase 2a study in patients with Alzheimer's disease with vascular pathology at the at the upcoming Alzheimer's Association International Conference 2021.
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat and others.
Cyclerion Therapeutics has a 52-week high of $8.96 and a 52-week low of $2.08.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
